Results 101 to 110 of about 28,392 (204)

Effectiveness of a Psychiatrist‐Led Clinic for Metabolic Health in Severe Mental Illness: A Retrospective Chart Review Study

Acta Psychiatrica Scandinavica, Volume 154, Issue 1, Page 74-88, July 2026.
ABSTRACT Background Psychotropic medications are associated with serious metabolic adverse effects, which contribute to an increased risk of cardiometabolic comorbidities in patients with severe mental illness (SMI). Several intervention strategies are available to mitigate these metabolic adverse effects; however, data on their utility in real‐world ...
Nicolette Stogios, Femin Prasad, Riddhita De, Kateryna Maksyutynska, Akash PrasannaKumar, Vittal Korann, Tariq Ahmed, Marcos Sanches, Leah Burton, Mohammed A. Alarabi, Tanner Isinger, Michelle Desanti, Rebecca Oliveira, Daphne J. Korczak, Ariel Graff‐Guerrero, Gary Remington, Margaret K. Hahn, Sri Mahavir Agarwal   +17 more
wiley   +1 more source

Health, Social and Recidivism Outcomes Among People Who Have Been Incarcerated in New South Wales, Australia: Study Protocol and Cohort Profile for the Prison Outcomes STudy (POST)

Drug and Alcohol Review, Volume 45, Issue 5, July 2026.
ABSTRACT Introduction We have been funded to examine post‐incarceration health and social outcomes for all people incarcerated in New South Wales, Australia, 2000–2022; assess treatment and services for drug dependence and serious mental illness; and project the impact of expanding intervention coverage. We will use a linked cohort, the Prison Outcomes
Louisa Degenhardt, Michael Farrell, Michael Doyle, Jack Stone, Chrianna Bharat, Matt Hickman, Marianne Martinello, Don Weatherburn, Kimberlie Dean, Joe Coyte, Christel Macdonald, Mary Ellen Harrod, Luke Grant, Gloria Larman, Peter Vickerman, Colette McGrath, Peter Thompson, Alison Churchill, Greg Dore, Thomas Santo Jr   +19 more
wiley   +1 more source

Olanzapine as a cause of urinary incontinence: a case report.

Iranian Journal of Psychiatry, 2012
Olanzapine, an atypical antipsychotic, is one of the most commonly used antipsychotics. Though olanzapine is commonly associated with endocrine side effects, it is generally well tolerated by most patients and is rarely associated with urinary ...
Mobolaji Usman Dada, Lateef Olutoyin Oluwole, Patrick T Adegun, Peter O Tareo   +3 more
doaj  

The Staging Model in Psychosis and Preventive Interventions: An Emerging Field With Debates on Conceptual Models and Interpretation of the Evidence Base

Early Intervention in Psychiatry, Volume 20, Issue 7, July 2026.
ABSTRACT Aims The staging model in psychiatry is heuristic and evolving, provoking debate and stimulating alternative views. This paper reviews major controversies in the field of staging and prevention of psychosis. Methods We review the literature on the classification model, the continuum model and the dynamic systems model applied to psychiatry ...
Mark van der Gaag, Cristina Mei, Barnaby Nelson, Maximus Berger, Marija Krcmar, G. Paul Amminger, Andreas Bechdolf, Paul Hutton, Pim Cuijpers, Alison R. Yung, Patrick D. McGorry   +10 more
wiley   +1 more source

Narrative Review of Catatonia in Psychosis and Eating Disorders: Common Intersections and Treatment Considerations

Early Intervention in Psychiatry, Volume 20, Issue 7, July 2026.
ABSTRACT Background Eating disorders (ED) and psychosis/psychotic‐spectrum disorders (PSD) have overlapping symptoms and may co‐occur in a variety of presentations. Due to its debilitating and life‐threatening risk, it is important for clinicians to be aware of how catatonia may present within these co‐occurrences.
Rosiel Elwyn
wiley   +1 more source

"Chill packs" self-administered olanzapine as psychiatric harm reduction for methamphetamine-induced psychosis: a narrative review of the existing evidence base. [PDF]

Harm Reduct J
Ruedisueli I, Marienfeld C, Tiefenthaler C, Lee A, Harvey-Vera A, Strathdee S, Friedman JR.   +6 more
europepmc   +1 more source

Samidorphan sadness: does the addition of samidorphan to olanzapine have prodepressive effects? [PDF]

Int Clin Psychopharmacol
Parkerson JA, Chaia AI, Lynch ST, Sterchele AN.   +3 more
europepmc   +1 more source

Olanzapine effectiveness on weight gain in anorexia nervosa patients: systematic review and meta-analysis. [PDF]

BMC Psychiatry
Alqurashi BF, Alserihi AR, Albariqi A, Alenazi AA, Alhindi Y, Alghamdi RL, Alotaibi BA, Abanmi SN, Alhejaili FA, Nahhas FH.   +9 more
europepmc   +1 more source

Olanzapine for Extended-Release Injectable Suspension for Subcutaneous Use (TV-44749) Designed to Avoid the Risk of PDSS: In Vitro Release Studies in Human Plasma and In Vivo Impact of Extrinsic Factors on Pharmacokinetics. [PDF]

Pharmaceutics
Bibi D, Steiner L, Krtalic I, Juretic M, Cetina-Cizmek B, Komlosi A, Loupe P, Ferderber K, Hallak H.   +8 more
europepmc   +1 more source

Olanzapine-Associated Hepatotoxicity in Bipolar Disorder: A Multicenter Real-World Study of Prevalence, Risk Factors, and Outcomes. [PDF]

Drug Des Devel Ther
Wang F, Lai X, Zhou S, Lin J, Xin H, Tao Z, Wang X, Zhang S, Liu Z, Tan H, Xiong Y.   +10 more
europepmc   +1 more source